AP -- Irish biopharmaceutical company Elan Corp. PLC reported a widening net loss in its first-quarter results Wednesday due to restructuring costs, but said sales improved for its key multiple sclerosis drug Tysabri.
AP -- Irish biopharmaceutical company Elan Corp. PLC reported a widening net loss in its first-quarter results Wednesday due to restructuring costs, but said sales improved for its key multiple sclerosis drug Tysabri.
